Tao Li

机构：AbbVie (United States) · ORCID：0000-0003-3672-6906

发表论文 40 篇 · 总被引 690 次 · h-index 17

代表论文

• NAT10 mediated ac4C acetylation driven m6A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and promotes osteosarcoma (2024 · Cell Communication and Signaling · 被引 60)
• M7G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma (2023 · Oncogene · 被引 58)
• BMAL1–HIF2A heterodimer modulates circadian variations of myocardial injury (2025 · Nature · 被引 50)
• The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy (2022 · ACS Chemical Biology · 被引 41)
• METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/β-catenin pathway (2021 · Annals of Translational Medicine · 被引 38)
• Comparative parallel analysis of RNA ends identifies mRNA substrates of a tRNA splicing endonuclease-initiated mRNA decay pathway (2021 · Proceedings of the National Academy of Sciences · 被引 28)